Revenue: As of FY2024 Q3, the actual value is USD 135.29 K.EPS: As of FY2024 Q3, the actual value is USD -0.93, beating the estimate of USD -4.35.<h3>Segment Revenue</h3><ul><li>Product Revenues – net of Discounts and Rebates: $135,293 for the three months ended September 30, 2024, compared to $51,188 for the same period in 2023, representing a 164.31% increase. For the nine months ended September 30, 2024, product revenues were $365,939, compared to $127,892 for the same period in 2023, a 186.13% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit (Loss): $23,606 for the three months ended September 30, 2024, compared to a loss of - $20,008 for the same period in 2023. For the nine months ended September 30, 2024, gross profit was $110,040, compared to a loss of - $200,401 for the same period in 2023.</li><li>Operating Expenses: Total operating expenses were $2,155,116 for the three months ended September 30, 2024, compared to $1,577,320 for the same period in 2023. For the nine months ended September 30, 2024, operating expenses were $7,792,318, compared to $3,142,995 for the same period in 2023.</li><li>Loss from Operations: - $2,118,692 for the three months ended September 30, 2024, compared to - $1,521,762 for the same period in 2023. For the nine months ended September 30, 2024, the loss was - $7,639,101, compared to - $3,260,422 for the same period in 2023.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $4,009,871 for the nine months ended September 30, 2024, compared to - $4,479,242 for the same period in 2023.</li><li>Net Cash Used in Investing Activities: - $1,887,016 for the nine months ended September 30, 2024, compared to - $49,326 for the same period in 2023.</li><li>Net Cash Provided by Financing Activities: $7,052,598 for the nine months ended September 30, 2024, compared to $6,474,565 for the same period in 2023.</li></ul><h3>Unique Metrics</h3><ul><li>Research Revenues: $12,818 for the three months ended September 30, 2024, compared to $75,566 for the same period in 2023. For the nine months ended September 30, 2024, research revenues were $43,177, compared to $82,974 for the same period in 2023.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to increase sales of Arakoda, conduct clinical trials to expand the number of patients who can use Tafenoquine for new indications, and reposition small molecule therapeutics for new indications.</li><li>Non-Core Business: The company has suspended its Phase IIB study for COVID-19 and is focusing on the commercialization of Arakoda for malaria and further evaluation of Tafenoquine for babesiosis and other diseases.</li></ul>

60 Degrees Pharmaceuticals | 10-Q: FY2024 Q3 Revenue: USD 135.29 K